| __timestamp | Axsome Therapeutics, Inc. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 10811000 |
| Thursday, January 1, 2015 | 2419289 | 33001000 |
| Friday, January 1, 2016 | 6343648 | 64936000 |
| Sunday, January 1, 2017 | 7206691 | 99909000 |
| Monday, January 1, 2018 | 9351522 | 127724000 |
| Tuesday, January 1, 2019 | 13598030 | 161524000 |
| Wednesday, January 1, 2020 | 28896749 | 182933000 |
| Friday, January 1, 2021 | 66646205 | 219982000 |
| Saturday, January 1, 2022 | 159253661 | 278139000 |
| Sunday, January 1, 2023 | 323123000 | 309799000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Axsome Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023.
Axsome Therapeutics started with a modest SG&A expense of approximately $1.4 million in 2014, which skyrocketed to over $320 million by 2023, marking a staggering increase of over 22,000%. In contrast, Ultragenyx Pharmaceutical began with $10.8 million in 2014 and reached around $310 million in 2023, reflecting a growth of about 2,770%.
While both companies have seen significant increases, Ultragenyx's expenses grew at a more consistent rate, suggesting a potentially more controlled approach to managing these costs. This comparison highlights the importance of strategic financial management in the biotech industry.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared